Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Otonomy Inc    OTIC

OTONOMY INC (OTIC)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
4.025(c) 3.95(c) 3.8(c) 3.75(c) 3.7(c) Last
165 446 273 050 204 937 155 545 218 505 Volume
-0.62% -1.86% -3.80% -1.32% -1.33% Change
More quotes
Financials (USD)
Sales 2018 1,20 M
EBIT 2018 -56,7 M
Net income 2018 -55,7 M
Debt 2018 -
Yield 2018 -
Sales 2019 1,33 M
EBIT 2019 -65,3 M
Net income 2019 -64,7 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 95,6x
Capi. / Sales2019 86,0x
Capitalization 115 M
More Financials
Company
Otonomy, Inc. engages in the research, development, and manufacture of biopharmaceutical products.The company portfolio includes therapeutics for diseases and disorders of the ear such as otitis media, acute otitis externa, balance disorders, Ménière's disease, tinnitus, cisplatin-induced hearing... 
More about the company
Surperformance© ratings of Otonomy Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on OTONOMY INC
03/15OTONOMY : Reports Fourth Quarter and Full Year 2017 Financial Results and Provid..
AQ
03/13MANAGEMENT TRACKS : WuXi NextCode, Assembly
AQ
03/12OTONOMY : to Present at Cowen and Company Health Care Conference
AQ
03/08OTONOMY : reports 4Q loss
AQ
03/08Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provi..
GL
03/08OTONOMY, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
03/08OTONOMY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
03/08OTONOMY INC : Otonomy, Inc. to Host Earnings Call
AC
03/06Otonomy to Present at Cowen and Company Health Care Conference
GL
03/06OTONOMY : Announces FDA Approval of OTIPRIO for Acute Otitis Externa
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/14Otonomy upgraded by Zacks Investment Research to buy. $4.75 PT.  
04/13Zacks Investment Research Lowers Otonomy $OTIC to Hold  
04/12TREND REVERSAL UP ALERT: $OTIC OTONOMY INC ? TradeIdeas via
1
04/09Otonomy $OTIC Lifted to Buy at Zacks Investment Research  
04/08Zacks Investment Research Lowers Otonomy $OTIC to Hold  
More tweets
Qtime:53
News from SeekingAlpha
03/19Premarket analyst action - healthcare 
03/14Otonomy (OTIC) Presents At 38th Annual Cowen And Company Healthcare Conferenc.. 
03/12PREMARKET GAINERS AS OF 9 : 05 am (03/12/2018) 
03/12Premarket analyst action - healthcare 
03/09Key events next week - healthcare (continued #3) 
Chart OTONOMY INC
Duration : Period :
Otonomy Inc Technical Analysis Chart | OTIC | US68906L1052 | 4-Traders
Technical analysis trends OTONOMY INC
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 11,7 $
Spread / Average Target 215%
EPS Revisions
Managers
NameTitle
David A. Weber President, Chief Executive Officer & Director
Jay B. Lichter Chairman
Paul E. Cayer Chief Financial, Business & Accounting Officer
Robert Michael Savel Chief Technical Officer
Katherine M. Bishop Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
OTONOMY INC-32.43%115
GILEAD SCIENCES3.31%96 094
VERTEX PHARMACEUTICALS5.89%40 153
REGENERON PHARMACEUTICALS-15.95%33 844
GENMAB23.13%12 797
BEIGENE LTD (ADR)71.91%8 998